Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, CME Group Inc’s stock clocked out at $270.28, up 0.58% from its previous closing price of $268.73. In other words, the price has increased by $0.58 from its previous closing price. On the day, 1.5 million shares were traded. CME stock price reached its highest trading level at $271.347 during the session, while it also had its lowest trading level at $268.37.
Ratios:
To gain a deeper understanding of CME’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.02. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
On July 24, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $305.
Morgan Stanley Upgraded its Equal-Weight to Overweight on April 08, 2025, while the target price for the stock was maintained at $301.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 25 ’25 when SHEPARD WILLIAM R bought 262 shares for $265.19 per share. The transaction valued at 69,603 led to the insider holds 258,459 shares of the business.
SHEPARD WILLIAM R bought 12 shares of CME for $3,069 on Sep 25 ’25. The Director now owns 2,466 shares after completing the transaction at $265.22 per share. On Sep 18 ’25, another insider, Marcus Jonathan L, who serves as the Sr MD General Counsel of the company, sold 392 shares for $262.00 each. As a result, the insider received 102,704 and left with 7,851 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CME now has a Market Capitalization of 97403559936 and an Enterprise Value of 99078053888. As of this moment, CME’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.16, and their Forward P/E ratio for the next fiscal year is 23.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.12 while its Price-to-Book (P/B) ratio in mrq is 3.50. Its current Enterprise Value per Revenue stands at 15.402 whereas that against EBITDA is 21.79.
Stock Price History:
The Beta on a monthly basis for CME is 0.42, which has changed by 0.22492635 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, CME has reached a high of $290.79, while it has fallen to a 52-week low of $208.75. The 50-Day Moving Average of the stock is -0.28%, while the 200-Day Moving Average is calculated to be 3.48%.
Shares Statistics:
It appears that CME traded 2.01M shares on average per day over the past three months and 1795000 shares per day over the past ten days. A total of 359.65M shares are outstanding, with a floating share count of 358.80M. Insiders hold about 0.44% of the company’s shares, while institutions hold 90.81% stake in the company. Shares short for CME as of 1757894400 were 4629679 with a Short Ratio of 2.30, compared to 1755216000 on 5080621. Therefore, it implies a Short% of Shares Outstanding of 4629679 and a Short% of Float of 1.2899999500000001.
Dividends & Splits
With its trailing 12-month dividend rate of 4.8, CME has a forward annual dividend rate of 4.87. Against a Trailing Annual Dividend Yield of 0.017861795. The stock’s 5-year Average Dividend Yield is 3.45. . The current Payout Ratio is 107.52% for CME, which recently paid a dividend on 2025-09-09 with an ex-dividend date of 2025-09-09. Stock splits for the company last occurred on 2012-07-23 when the company split stock in a 5:1 ratio.
Earnings Estimates
The company has 14.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $2.68, with high estimates of $2.87 and low estimates of $2.57.
Analysts are recommending an EPS of between $11.53 and $10.86 for the fiscal current year, implying an average EPS of $11.13. EPS for the following year is $11.6, with 18.0 analysts recommending between $12.14 and $10.96.
Revenue Estimates
In . The current quarter, 10 analysts expect revenue to total $1.57B. It ranges from a high estimate of $1.68B to a low estimate of $1.5B. As of . The current estimate, CME Group Inc’s year-ago sales were $1.58BFor the next quarter, 10 analysts are estimating revenue of $1.59B. There is a high estimate of $1.7B for the next quarter, whereas the lowest estimate is $1.55B.
A total of 16 analysts have provided revenue estimates for CME’s current fiscal year. The highest revenue estimate was $6.71B, while the lowest revenue estimate was $6.41B, resulting in an average revenue estimate of $6.51B. In the same quarter a year ago, actual revenue was $6.13BBased on 16 analysts’ estimates, the company’s revenue will be $6.8B in the next fiscal year. The high estimate is $7.27B and the low estimate is $6.48B.
